5–fluorouracil, adriamycin, cyclophosphamide (FAC) vs. 5–fluorouracil, epirubicin, cyclophosphamide (FEC) in metastatic breast cancer

Massimo Lopez, Paola Papaldo, Luigi Di Lauro, Patrizia Vici, Silvia Carpano, Ettore M S Conti

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

94 evaluable patients with metastatic breast cancer were randomly assigned to 5-fiuorouracil, adriamycin, and cyclophosphamide (FAC) or 5-fluorouracil, epirubicin, and cyclophosphamide (FEC), with cycles repeated every 3 weeks. The objective response rate to FAC was 46% versus 44% to FEC. There was no significant difference in the median duration of response and median survival for the two regimens. Toxicity was more frequent and more pronounced in patients receiving FAC. Results indicate therapeutic equivalence of the two regimens and reduced toxicity of the epirubicin arm.

Original languageEnglish
Pages (from-to)1-5
Number of pages5
JournalOncology
Volume46
Issue number1
DOIs
Publication statusPublished - 1989

Fingerprint

Epirubicin
Fluorouracil
Doxorubicin
Cyclophosphamide
Breast Neoplasms
Survival

Keywords

  • Breast cancer
  • Chemotherapy
  • Epirubicin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

5–fluorouracil, adriamycin, cyclophosphamide (FAC) vs. 5–fluorouracil, epirubicin, cyclophosphamide (FEC) in metastatic breast cancer. / Lopez, Massimo; Papaldo, Paola; Di Lauro, Luigi; Vici, Patrizia; Carpano, Silvia; Conti, Ettore M S.

In: Oncology, Vol. 46, No. 1, 1989, p. 1-5.

Research output: Contribution to journalArticle

Lopez, Massimo ; Papaldo, Paola ; Di Lauro, Luigi ; Vici, Patrizia ; Carpano, Silvia ; Conti, Ettore M S. / 5–fluorouracil, adriamycin, cyclophosphamide (FAC) vs. 5–fluorouracil, epirubicin, cyclophosphamide (FEC) in metastatic breast cancer. In: Oncology. 1989 ; Vol. 46, No. 1. pp. 1-5.
@article{02a5e6e6efeb4bb79ed272282ff2f146,
title = "5–fluorouracil, adriamycin, cyclophosphamide (FAC) vs. 5–fluorouracil, epirubicin, cyclophosphamide (FEC) in metastatic breast cancer",
abstract = "94 evaluable patients with metastatic breast cancer were randomly assigned to 5-fiuorouracil, adriamycin, and cyclophosphamide (FAC) or 5-fluorouracil, epirubicin, and cyclophosphamide (FEC), with cycles repeated every 3 weeks. The objective response rate to FAC was 46{\%} versus 44{\%} to FEC. There was no significant difference in the median duration of response and median survival for the two regimens. Toxicity was more frequent and more pronounced in patients receiving FAC. Results indicate therapeutic equivalence of the two regimens and reduced toxicity of the epirubicin arm.",
keywords = "Breast cancer, Chemotherapy, Epirubicin",
author = "Massimo Lopez and Paola Papaldo and {Di Lauro}, Luigi and Patrizia Vici and Silvia Carpano and Conti, {Ettore M S}",
year = "1989",
doi = "10.1159/000226671",
language = "English",
volume = "46",
pages = "1--5",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "1",

}

TY - JOUR

T1 - 5–fluorouracil, adriamycin, cyclophosphamide (FAC) vs. 5–fluorouracil, epirubicin, cyclophosphamide (FEC) in metastatic breast cancer

AU - Lopez, Massimo

AU - Papaldo, Paola

AU - Di Lauro, Luigi

AU - Vici, Patrizia

AU - Carpano, Silvia

AU - Conti, Ettore M S

PY - 1989

Y1 - 1989

N2 - 94 evaluable patients with metastatic breast cancer were randomly assigned to 5-fiuorouracil, adriamycin, and cyclophosphamide (FAC) or 5-fluorouracil, epirubicin, and cyclophosphamide (FEC), with cycles repeated every 3 weeks. The objective response rate to FAC was 46% versus 44% to FEC. There was no significant difference in the median duration of response and median survival for the two regimens. Toxicity was more frequent and more pronounced in patients receiving FAC. Results indicate therapeutic equivalence of the two regimens and reduced toxicity of the epirubicin arm.

AB - 94 evaluable patients with metastatic breast cancer were randomly assigned to 5-fiuorouracil, adriamycin, and cyclophosphamide (FAC) or 5-fluorouracil, epirubicin, and cyclophosphamide (FEC), with cycles repeated every 3 weeks. The objective response rate to FAC was 46% versus 44% to FEC. There was no significant difference in the median duration of response and median survival for the two regimens. Toxicity was more frequent and more pronounced in patients receiving FAC. Results indicate therapeutic equivalence of the two regimens and reduced toxicity of the epirubicin arm.

KW - Breast cancer

KW - Chemotherapy

KW - Epirubicin

UR - http://www.scopus.com/inward/record.url?scp=0024553598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024553598&partnerID=8YFLogxK

U2 - 10.1159/000226671

DO - 10.1159/000226671

M3 - Article

VL - 46

SP - 1

EP - 5

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 1

ER -